The President of the Republic et al. v. Ali Ayyoub et al., Judgment, on Appeal No. 74236/62 J S. at https://eastlaws.com. Supreme Administrative Court of Egypt, January 16, 2017

Moli, Ginevra Le

doi:10.2139/ssrn.3785157

Cited by 1 publication

(4 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The eight guidelines had 144 recommendations in total; 120 recommendations were evaluated according to grading system however 24 did not have any grading system. 3,[6][7][8][9][10][11][12] All guidelines, except ESC and NSW, have their owned grading system. However, the guidelines used different grading systems.…”

Section: Search Resultsmentioning

confidence: 99%

“…NCCN, CCS and ESC indicated a lack of high-quality data on the benefits of screening and monitoring by biomarkers nevertheless, they recommended considering biomarker assays in high-risk patients. 3,11 NSW and SIOG did not recommend biomarkers for monitoring. ASCO suggests performing baseline assessments of biomarkers (troponin I and BNP) and periodic measurements during therapy (every cycle) to potentially identify patients who require further cardiac assessment or who are at risk for cardiotoxicity, despite limited data on the effectiveness of this strategy.…”

Section: Discussionmentioning

confidence: 99%

“…3,7,10,12 The other guidelines, NCCN, ESMO and ASCO did not mention gender as a risk factor. 3,[6][7][8][9][10][11][12] Other risk factors included concomitant chemotherapy such as alkylating agents, antimicrotubular agents or immuno-and targeted therapies, were considered risk factors in ESC, while ASCO, SEOM, SIOG and ESMO mentioned trastuzumab only NSW mentioned that any other potentially cardiotoxic drugs such as trastuzumab, paclitaxel, streptozocin, cyclosporin, dacarbazine, dactinomycin, etoposide, cyclophosphamide, ifosfamide, mitomycin, melphalan, vincristine and bleomycin may increase the risk of cardiotoxicity. [6][7][8][9][10] All guidelines considered age as a risk factor, but there were discrepancies with regards to the age at highest risk; ESMO indicates a range of younger than 10 years and older than 75 years, while ESC indicates a range of younger than 18 years and older than 65 years as high risk, NCCN only mentioned age above 65 years, SEOM mentions age younger than 15 years and older than 65 years, and ASCO mentions only older than 60 years.…”

Section: Discussionmentioning

confidence: 99%

“…Management of cardiotoxicity (16 items) were ASCO (3 items), CCS (11), ESC (6), ESMO (15), NCCN (5), NSW (7), SEMO (7) and SIOG (5). Complete history and physical examination item and referral to cardiologist were mentioned in all guidelines nevertheless the other 14 items were different amongst guidelines.…”

Section: Comparison Of Guidelines' Recommendationsmentioning

confidence: 99%

See 3 more Smart Citations

Critical appraisal of clinical guidelines for prevention and management of doxorubicin-induced cardiotoxicity

Moustafa

Viljoen

Perumal-Pillay

et al. 2022

J Oncol Pharm Pract

View full text Add to dashboard Cite

Objective Doxorubicin is a valuable chemotherapeutic drug; however, it is associated with a high risk of cardiotoxicity. Several institutions and organizations have developed guidelines for risk factor assessment, monitoring and prevention strategies against chemotherapy-induced cardiotoxicity. This review aimed to assess the quality of current practice guidelines, using the Appraisal of Guidelines for Research and Evaluation II (AGREE II). This tool was used to compare the recommendations with regards to their strength and evidence recommendations were based on. Data Sources This review identified guidelines in literature from January 1960 to February 6, 2022, through a systematic search that included PubMed, EMBASE, MEDLINE, Cochrane Database and Google Scholar. The quality, consistency and the strength of supporting evidence was evaluated using the AGREE II method. Data Summary Eight guidelines met the inclusion criteria and 144 recommendations were extracted from these guidelines. The results from the AGREE II evaluation showed that the total assessment scores of guidelines ranged from 2 to 5, indicating the guidelines need modifications. The recommendations were evaluated according to the references used, and it was found that 12 (11%) recommendations had high evidence, 36 (33%) had moderate evidence, 38 (35.19%) had low and 22 (20.37%) had insufficient evidence. Recommendations for risk factors assessment, prophylaxis of cardiotoxicity, management of cardiotoxicity and monitoring of cardiotoxicity were quite varied amongst the different guidelines evaluated. Conclusions All studied guidelines need modifications as per the AGREE II evaluating tool. Several shortcomings were identified, including a lack of evidence-based studies supporting the recommendations in the guidelines.

show abstract